Latest News & Features
Americas
In 2015 the US Federal Circuit resolved the biosimilars case of Amgen v Sandoz. But the parties did not stop there, meaning the Supreme Court could potentially review it. LSIPR looks at the consequences of a possible review. 31 May 2016
Americas
A firm advocate of ‘open innovation’, Novartis is setting aside rivalries and working on a number of projects to ensure patients get the best treatments as quickly as possible. LSIPR spoke to Graham Stuart of the company about some of the work. 31 May 2016
Americas
Each ‘patent dance’ dispute between biologics and biosimilars companies will present its own nuances in the process of solving the mystery, argue Lisa Pensabene and Daniel O'Boyle of O’Melveny & Myers. 26 May 2016
Africa
It is likely that many patent applications directed to CRISPR technology will be filed in India, says Hemant Singh of Inttl Advocare, who analyses some of the early applications and the rules on patentability. 19 May 2016
Big Pharma
There is a lack of judicial guidance in Europe on the issue of third party supplementary protection certificates (SPCs), otherwise known as “SPC squatting”, as Trevor Cook of WilmerHale explains. 12 May 2016
Americas
CRISPR is only part of the gene editing story, and by studying the patents associated with all of the various methods, a much clearer picture of the entire field can be generated, says Tony Trippe, senior patent analyst for Thomson Reuters. 5 May 2016
Africa
Ahead of the English Court of Appeal’s hearing in May in the Warner-Lambert case on second medical use patents, Charlotte Weekes and Tamsin Cornwell of Pinsent Masons examine some of the unanswered questions. 28 April 2016
Americas
Unlike in the EU, Canada does not have additional pharma patent protection to compensate for regulatory delays, but that looks set to change, as Shirley Liang, an IP lawyer in Canada, explains. 21 April 2016
Asia
The Indian government has invited public comments on draft regulatory guidelines for biosimilars, while patent law in this area has still to take shape. Sameer Sah, Nisha Austine and Jahnvi Shah of Khaitan & Co report. 14 April 2016
Americas
The BPCIA requires a biosimilar applicant to notify the reference product sponsor of its drug no later than 180 days before the first commercial marketing date. Darryl Woo, Erin Ator Thomson, Janice Ta and Wendy Wang of Vinson & Elkins report on some of the pressing issues in this area. 7 April 2016